Riociguat
Antihypertensives For Pulmonary Arterial Hypertension
Sold as ADEMPAS
- Drug class
- Antihypertensives For Pulmonary Arterial Hypertension
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 19
Overview
Riociguat is an active pharmaceutical ingredient in the Antihypertensives For Pulmonary Arterial Hypertension group (C02KX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 10 | August 29, 2025 |
| GB United Kingdom | MHRA | 8 | January 9, 2026 |
| EU European Union | EMA | 1 | May 22, 2026 |
CACanada· Health Canada
10 products
Uses
Pulmonary Hypertension Sandoz Riociguat (Riociguat Tablets) is indicated for the treatment of: • inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) • persistent or recurrent CTEPH after surgical treatment • pulmonary arterial hypertension (PAH, WHO Group 1), as monotherapy or in combination with endothelin receptor antagonists in adult patients (≥18 years of age) with WHO Functional Class II or III pulmonary hypertension.
Sandoz Riociguat should only be used by clinicians experienced in the diagnosis and treatment of CTEPH or PAH. 3 Pediatrics). Therefore, Health Canada has not authorized an indication for pediatric use. 4 Geriatrics).
How to take
GBUnited Kingdom· MHRA
8 products
Uses
1). 1). 1).
How to take
EUEuropean Union· EMA
1 product
Uses
1). 1). 1).
How to take
Drug interactions
Known interactions involving Riociguat. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02533545 · revised August 29, 2025
- [2]MHRA (UK) · PLGB000100671 · revised January 2, 2026
- [3]European Medicines Agency · EMEA/H/C/002737 · revised May 22, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.